Xiangxue Pharmaceutical (SHE:300147) — Market Cap & Net Worth
Market Cap & Net Worth: Xiangxue Pharmaceutical (300147)
Xiangxue Pharmaceutical (SHE:300147) has a market capitalization of $969.59 Million (CN¥6.63 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #9242 globally and #2494 in its home market, demonstrating a -1.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xiangxue Pharmaceutical's stock price CN¥10.02 by its total outstanding shares 661279045 (661.28 Million). Analyse how efficiently does Xiangxue Pharmaceutical generate cash to see how efficiently the company converts income to cash.
Xiangxue Pharmaceutical Market Cap History: 2015 to 2026
Xiangxue Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $2.37 Billion to $969.59 Million (-6.37% CAGR).
Xiangxue Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xiangxue Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.51x
Xiangxue Pharmaceutical's market cap is 0.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.37 Billion | $1.46 Billion | $177.30 Million | 1.62x | 13.34x |
| 2016 | $1.23 Billion | $1.86 Billion | $66.02 Million | 0.66x | 18.63x |
| 2017 | $855.51 Million | $2.19 Billion | $65.94 Million | 0.39x | 12.97x |
| 2018 | $588.07 Million | $2.50 Billion | $56.44 Million | 0.23x | 10.42x |
| 2019 | $853.35 Million | $2.79 Billion | $76.51 Million | 0.31x | 11.15x |
| 2020 | $866.05 Million | $3.07 Billion | $98.42 Million | 0.28x | 8.80x |
| 2021 | $780.90 Million | $2.97 Billion | -$688.47 Million | 0.26x | N/A |
| 2022 | $587.37 Million | $2.19 Billion | -$530.06 Million | 0.27x | N/A |
| 2023 | $498.34 Million | $2.30 Billion | -$388.96 Million | 0.22x | N/A |
| 2024 | $945.40 Million | $1.86 Billion | -$858.56 Million | 0.51x | N/A |
Competitor Companies of 300147 by Market Capitalization
Companies near Xiangxue Pharmaceutical in the global market cap rankings as of May 4, 2026.
Key companies related to Xiangxue Pharmaceutical by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Xiangxue Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Xiangxue Pharmaceutical's market cap moved from $2.37 Billion to $ 969.59 Million, with a yearly change of -6.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥969.59 Million | +10.11% |
| 2025 | CN¥880.57 Million | -6.86% |
| 2024 | CN¥945.40 Million | +89.71% |
| 2023 | CN¥498.34 Million | -15.16% |
| 2022 | CN¥587.37 Million | -24.78% |
| 2021 | CN¥780.90 Million | -9.83% |
| 2020 | CN¥866.05 Million | +1.49% |
| 2019 | CN¥853.35 Million | +45.11% |
| 2018 | CN¥588.07 Million | -31.26% |
| 2017 | CN¥855.51 Million | -30.47% |
| 2016 | CN¥1.23 Billion | -47.99% |
| 2015 | CN¥2.37 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Xiangxue Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $969.59 Million USD |
| MoneyControl | $969.59 Million USD |
| MarketWatch | $969.59 Million USD |
| marketcap.company | $969.59 Million USD |
| Reuters | $969.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more